Comparative Pharmacology
Head-to-head clinical analysis: IMMPHENTIV versus TECFIDERA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMMPHENTIV versus TECFIDERA.
IMMPHENTIV vs TECFIDERA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
IMMPHENTIV is an anti-PD-1 monoclonal antibody that binds to the PD-1 receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands, thereby restoring antitumor T-cell function.
Dimethyl fumarate (DMF) is a methyl ester of fumaric acid. The exact mechanism of action in multiple sclerosis is unknown. It is thought to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway, which induces antioxidant response elements and upregulates cytoprotective genes, reducing oxidative stress and inflammation.
4 mg/kg intravenously every 2 weeks until disease progression or unacceptable toxicity.
240 mg orally twice daily.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
The terminal elimination half-life of monomethyl fumarate (MMF) is approximately 1 hour. Due to rapid metabolism and elimination, MMF does not accumulate with multiple doses. No context of clinical significance is observed for accumulation.
Renal (70% as unchanged drug), biliary/fecal (30% as metabolites and unchanged drug).
Dimethyl fumarate is extensively metabolized; less than 1% is excreted unchanged in urine. The major metabolite, monomethyl fumarate, is further metabolized via the tricarboxylic acid cycle. Excretion occurs primarily as CO2 via exhalation, with about 60% of a dose recovered as CO2. Renal excretion accounts for approximately 16% of the dose as metabolites, and fecal excretion accounts for about 1%.
Category C
Category C
Immunomodulator
Immunomodulator, Fumaric Acid Derivative